These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8489746)

  • 1. Development of a preclinical model for hormonal therapy of human endometrial carcinomas.
    Satyaswaroop PG
    Ann Med; 1993 Apr; 25(2):105-11. PubMed ID: 8489746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model.
    Zaino RJ; Satyaswaroop PG; Mortel R
    Cancer Res; 1985 Feb; 45(2):539-41. PubMed ID: 3967228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat.
    Horn DW; Vollmer G; Deerberg F; Schneider MR
    J Cancer Res Clin Oncol; 1993; 119(8):450-6. PubMed ID: 8509435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphology of human uterine cancer in nude mice. Effects of hormone and antihormone treatment.
    Zaino RJ; Satyaswaroop PG; Mortel R
    Arch Pathol Lab Med; 1984 Jul; 108(7):571-8. PubMed ID: 6547322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor.
    Satyaswaroop PG; Clarke CL; Zaino RJ; Mortel R
    Cancer Lett; 1992 Feb; 62(2):107-14. PubMed ID: 1540937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y; Tong J; Ai Z; Wang J; Teng Y
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
    Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
    Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma.
    Satyaswaroop PG; Zaino R; Clarke CL; Mortel R
    J Steroid Biochem; 1987; 27(1-3):431-8. PubMed ID: 2961935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
    Mitsushita J; Toki T; Kato K; Fujii S; Konishi I
    Gynecol Oncol; 2000 Oct; 79(1):129-32. PubMed ID: 11006045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia.
    Carlson JA; Allegra JC; Day TG; Wittliff JL
    Am J Obstet Gynecol; 1984 May; 149(2):149-53. PubMed ID: 6232850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone therapy for uterine corpus cancer--introduction].
    Sugiyama T; Izutsu T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
    Zhao S; Chen X; Lu X; Yu Y; Feng Y
    Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
    Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
    Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
    van den Berg HW; Martin J; Lynch M
    Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growth regulation of sex steroid hormone in endometrial carcinoma transplanted into nude mice].
    Kato Y; Morisawa T; Kuramoto H
    Hum Cell; 1991 Jun; 4(2):165-70. PubMed ID: 1835653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal treatment of endometrial cancer: past, present and future.
    Podczaski E; Mortel R
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone therapy for patients with advanced or recurrent endometrial cancer.
    Lee WL; Yen MS; Chao KC; Yuan CC; Ng HT; Chao HT; Lee FK; Wang PH
    J Chin Med Assoc; 2014 May; 77(5):221-6. PubMed ID: 24694672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal therapy for endometrial adenocarcinoma].
    Susumu N; Aoki D; Suzuki N; Nozawa S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
    Bonte J
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):335-41. PubMed ID: 6526120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.